Last reviewed · How we verify

NCT03929822

Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis

Terminated Last updated 20 January 2023
What this trial tests

trial testing Contrast-Enhanced Spectral Mammography in Breast Screening in 32 participants. Terminated before completion.

Timeline
23 April 2019
Primary endpoint
19 January 2023
19 January 2023

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
StatusTerminated
Study typeOBSERVATIONAL
Enrollment32
Start date23 April 2019
Primary completion19 January 2023
Estimated completion19 January 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

30 and older, female only, with Breast Screening. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test whether contrast-enhanced spectral mammography (CESM) may be able to reduce the number of unnecessary biopsies in women whose screening mammograms had abnormal findings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Screening

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03929822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing